REVOLADE CAN GIVE CONFIDENCE IN ACHIEVING EARLY PLATELET RESPONSE 1,2*
REVOLADE achieved an early platelet response in ITP patients in the RAISE study:1
- Median platelet count increased from 16,000/µL (IQR 8,000–22,000/µL) to 36,000/µL (IQR 13,000–74,000/µL) after 1 week of REVOLADE treatment
- In comparison, the median platelet count for the placebo group remained between 17,500/µL (IQR 8,000–29,000/µL) and 23,000/µL (IQR 10,000–40,000/µL)
- Some patients achieved a response* as early as Day 8
*Response: platelet count higher than 50,000/µL at least once in the absence of rescue therapy.
Abbreviations: IQR, interquartile range; ITP, immune thrombocytopenia.
- Cheng G, et al. Lancet. 2011;377:393–402.
- Data on ﬁle REVDOF001.